日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden

真性红细胞增多症和原发性血小板增多症患者接受聚乙二醇干扰素α治疗后外周血淋巴细胞的变化及其与JAK2V617F等位基因负荷的相关性

Magdalena Kovacsovics-Bankowski ,Todd W Kelley ,Olga Efimova ,Soo Jin Kim ,Andrew Wilson ,Sabina Swierczek ,Josef Prchal

T-cell acute leukemia 1 (TAL1) regulation of erythropoietin receptor and association with excessive erythrocytosis

细胞急性白血病 1 (TAL1) 对促红细胞生成素受体的调节及其与红细胞增多症的关系

Heather Rogers, Li Wang, Xiaobing Yu, Mawadda Alnaeeli, Kairong Cui, Keji Zhao, James J Bieker, Josef Prchal, Suming Huang, Babette Weksler, Constance Tom Noguchi

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

JAK 激酶抑制剂 CP-690,550 可抑制携带 JAK2V617F 突变的人类真性红细胞增多症细胞的生长

Taghi Manshouri, Alfonso Quintás-Cardama, Roberto H Nussenzveig, Amos Gaikwad, Zeev Estrov, Josef Prchal, Jorge E Cortes, Hagop M Kantarjian, Srdan Verstovsek